

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>BIOGEN IDEC INC</u> (Last) (First) (Middle) <u>14 CAMBRIDGE CENTER</u> (Street) <u>CAMBRIDGE MA 02142</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TARGETED GENETICS CORP /WA/ [TGEN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/06/2002</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.01 Par Value	09/30/2002		J		104,854 ⁽¹⁾	A	\$0.55	9,400,516	I	By Biogen Idec MA, Inc. ⁽²⁾
Common Stock, \$0.01 Par Value	11/06/2002		J		210,819 ⁽³⁾	D	\$1.07	9,611,335	I	By Biogen Idec MA, Inc. ⁽²⁾
Common Stock, \$0.01 Par Value	08/15/2003		P		2,515,843 ⁽⁴⁾	A	\$1.91	12,127,178	I	By Biogen Idec MA, Inc. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
BIOGEN IDEC INC
 (Last) (First) (Middle)
14 CAMBRIDGE CENTER
 (Street)
CAMBRIDGE MA 02142
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
BIOGEN IDEC MA INC
 (Last) (First) (Middle)
14 CAMBRIDGE CENTER
 (City) (State) (Zip)

(Street)	CAMBRIDGE	MA	02142
(City)		(State)	(Zip)

Explanation of Responses:

1. The reporting person received these shares as additional merger consideration for its preferred shares of Genovo, Inc. exchanged in the merger of a subsidiary of Targeted Genetics Corporation with and into Genovo on September 19, 2000, pursuant to the exercise of the Genzyme Corporation's stock option in connection with the merger.
2. Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA, Inc., fka Biogen, Inc.
3. The reporting person forfeited these shares on 11/6/2002 to Targeted Genetics in connection with certain of its indemnification claims under the Agreement and Plan of Merger, dated August 8, 2000, among Genovo, Inc., Targeted Genetics, a wholly-owned subsidiary of Targeted Genetics and the reporting person, a stockholder of Genovo.
4. The reporting person purchased these shares on 8/15/2003 upon exercise by Targeted Genetics of its right to put such shares to the reporting person for purchase under the Funding Agreement dated as of August 8, 2000 between Targeted Genetics and the reporting person.

Remarks:

Exhibit List Exhibit 99- Joint Filer Information

/s/ Raymond G. Arner, Acting 07/12/2005
General Counsel

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 Joint Filer Information

Name: Biogen Idec MA, Inc.

Address: 14 Cambridge Center
Cambridge, Massachusetts 02142

Designated Filer: Biogen Idec Inc.

Issuer and Ticker Symbol: Targeted Genetics Corporation (TGEN)

Date of Earliest
Transaction Required
to be Reported: September 30, 2002

Signature: By: /s/ Michael Phelps
Name: Michael Phelps
Title: Treasurer